All doses of tirzepatide and semaglutide increased the risk for gastrointestinal adverse events versus placebo, with tirzepatide 15 mg yielding the highest risk for nausea (risk ratio [RR], 3.57), vomiting (RR, 4.35), and diarrhea (RR, 2.04)
If it triggers gastrointestinal symptoms, consideration should be given to delaying dose escalation or reducing the dose until symptoms improve
The co-founder and co-CEO of Our Place on how her daughter changed the way she designs, leads, and defines success
Targeted Supplement Support : My patients experience significantly fewer side effects when supplementing with a specific protocol of digestive enzymes, ginger, and gut-healing nutrients
A little bowl of soup with shredded chicken can be more useful than a large plate you dread eating
These pigmented areas are usually benign and do not require treatment